The pleural invasion (PL) score is a useful prognostic indicator in lung cancer. However, in many cases, the cancer may exfoliate itself into the pleural cavity and may progress to a malignant pleural effusion without invading the parietal pleura. This stage is not currently evaluated, but it is detectable by means of the pleural lavage cytology (PLC). However, PLC's contribution to TNM staging has not yet been clarified. The purpose of this investigation was to demonstrate the usefulness of PLC in the precise staging of patients with such an occult pleural dissemination.
INTRODUCTION
The peripheral lung cancer tends to grow by invading the visceral pleura and then progressing to the parietal pleura. This progression is expressed by a pleural invasion (PL) score from PL0 to PL3, which is considered to be useful for predicting prognosis by providing supplemental information to TNM staging [1] . However, it is evident that lung cancer may progress via another route. After reaching the surface of the visceral pleura, cancer cells may exfoliate themselves into the pleural cavity and potentially progress to a malignant pleural effusion. Although this type of progression is not currently considered for staging purposes, it is detectable by the cytological examination of the pleural cavity, such as via pleural lavage cytology (PLC). Several reports have suggested that PLC findings obtained during surgery are an important prognostic indicator [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . However, PLC's contribution to TNM staging has not yet been clarified. The purpose of this investigation was to demonstrate the usefulness of PLC in the precise staging of patients with such an occult pleural dissemination.
operation between 2000 and 2007. Patients with obvious malignant pleural effusion or with Stage IV disease were excluded before the registration. A total of 3493 patients were registered from 12 institutes in which PLC had been routinely examined. After excluding the patients against eligible criteria (small cell carcinoma, 40; low-grade malignancy, 4; multiple primary lung cancer or pulmonary metastasis, 20; M1a or M1b, 62; incomplete data, 136), a total of 3231 patients were included in the study.
Methods
PLC was performed by washing the thoracic cavity with 20-500 ml of physiological saline immediately after opening the thoracic cavity during surgery; a 10-20 ml of specimen was collected for cytological examination. Actually, in most institutes, physiological saline of ≤100 ml was used for lavage fluid. Washing with 500 ml, which was used in two institutes, may increase the falsenegative findings due to the over-dilution. However, according to the result of preliminary analysis that incidence of positive PLC findings per each institutes had no statistical difference (P = 0.208), we accepted the registration from the 500 ml institutes. We recommend the amount of lavage fluid not to exceed 100 ml. In this study, a routine radical operation for lung cancer, with mediastinal lymph node dissection conforming to the General Rule for Clinical and Pathological Record of Lung Cancer (6th edition) by the Japanese Lung Cancer Society [15] , was performed in all patients irrespective of their PLC results. In cases where parietal pleural invasion was identified, combined resection of the pleura and chest wall, if necessary, was performed. Postoperative pathological evaluation was performed by each institute's pathologist to determine the histology, tumour size and pathological TNM. pleural invasion was also evaluated by the pathologist as a PL score ranging from PL0 to PL3 as follows: PL0, tumour within the subpleural lung parenchyma; PL1, invasion beyond the elastic layer; PL2, invasion to the pleural surface; PL3, invasion to the parietal pleura [1] . Data were collected from databases, including the result of PLC, age, gender, survival time, dead or alive (all death or censored), operative procedure, actual disease-free time, site of recurrence and information about adjuvant chemotherapy. The pathological T ( pT) and pathological N ( pN) scores were converted to the new 7th Edition TNM Classification [16, 17] , but some stage migration of the N score could not be avoided because of the discontinuity between the Naruke map and the Rusch-Asamura map [18] .
Statistical analyses
In a background analysis, age, gender, histology, pathological stage ( p-Stage), pT, pN and PL scores were compared between the PLC-positive (PLC + ) group and the PLC-negative (PLC − ) group. Differences were assessed statistically using a t-test for the numerical variables and a χ 2 test for the categorical variables. A P-value of <0.05 was considered to be statistically significant. Survival analysis was performed first with the entire cohort; next, subset analyses were performed on the histology (adenocarcinoma, squamous cell carcinoma and others), p-Stage, pT, pN and PL scores. Survival curves were generated via the Kaplan-Meier method, and statistical differences between the PLC + group and PLC − group were evaluated by the logrank test. A multivariate analysis using a Cox proportional hazard model (Cox analysis) was also performed to evaluate the significance of prognostic factors (PLC, age, gender, tumour size, pN and PL scores), and the hazard ratio, likelihood ratio χ 2 statistic (χ 2 ) and P-value ( probability > χ 2 ) were estimated. All statistical analyses were performed using StatMate IV software (ATMS, Tokyo, Japan) or JMP 8.0 software (SAS Institute Japan, Tokyo, Japan).
Integration of the pleural lavage cytology-positive findings with the existing staging factors
After the evaluation of the six prognostic factors, integration of the PLC + findings with the existing staging factors was attempted for convenience of TNM staging. According to the results of the subset analysis and theoretical considerations, integration of the PLC + findings with the PL score was considered to be most reasonable. Seeking the appropriate PL score matching to the PLC + findings, the Cox analysis was re-estimated using a corrected PL score by replacing the score of underestimated cases with a higher score in a gradual manner (PL1, PL2 and then PL3). The reliability of each Cox proportional hazard model was evaluated by the χ 2 and P-value with regard to the whole model and to the PL score. Since the P-values were too small to compare with each other, χ 2 was used in this instance. The model with the largest χ 2 has the smallest P-value and, therefore, is the most reliable model.
RESULTS
The incidence of PLC + findings was 4.58% (148/3231). In a background analysis, histology, pathological stage ( p-Stage), pT, pN and PL scores had significant differences between the groups ( Table 1 ). It was suspected that the PLC + group consisted of patients whose cancer had advanced to a particular stage. Regarding to the higher incidence of N2 disease in the PLC + group, cancer may migrate the lymphatic channels of the pleura and may cause the lymph node metastasis. However, the recurrence rate associated with the mediastinal-supraclavicular lymph node enlargement had no statistical difference (P = 0.450) between the PLC + group and the PLC − group, which was estimated to be 8.8 and 6.6%, respectively. The survival curve of the PLC + group was significantly worse than that of the PLC − group in terms of both the overall survival (OS) and disease-free survival (DFS) (Fig. 1) . Differences in the subset analysis are shown in Table 2 , and DFS curves for each p-Stage and each PL score are shown in Figs 2 and 3 , respectively. In Stages IA and IB, the survival curves of the PLC + group were significantly worse than those of the PLC − group. As for the PL score, the survival curves of the PLC + group were also worse in the PL0 and PL1 groups. However, differences were not observed in the PL2 and PL3 groups. These findings suggested that the PLC + patients should not be included in these earlier stages.
In an analysis of recurrent cases, the incidence of a malignant pleural effusion or obvious pleural dissemination ( pleuritis carcinomatosa) was 17.6% (26/148) in the PLC + group, compared with 2.8% (86/3083) in the PLC − group, a significant difference (P < 0.001). However, no difference was apparent with regard to sites of distant metastasis. For this reason, it was concluded that PLC + findings was a preliminary stage of a malignant pleural effusion.
Among the six variables analysed by Cox analysis, all were statistically significant in terms of OS and DFS (Table 3) . PLC + findings were confirmed as a significantly poor prognostic factor in both OS (P = 0.016) and DFS (P = 0.026). However, it would be more convenient if the PLC + findings were integrated with one of the existing TNM staging factors. A total of 89 cases (60.1%) with PLC + findings had been diagnosed as either PL1 or PL0, which the subset analysis showed to be underestimations of the disease stage. To find the accurate PL score for positive PLC findings, the Cox analysis was re-estimated using the PL score upgraded stepwise. The χ 2 regarding to the whole model reached its maximum value by a correction to PL3 in both OS (uncorrected, PL2, PL3; 654.67, 658.99, 659.04) and DFS Disease-free survival Histology Adenocarcinoma P < 0.001* P < 0.001* Squamous cell carcinoma P = 0.496 P = 0.188 Others P = 0.877 P = 0.837 Pathological stage IA P = 0.045* P < 0.001* IB P = 0.010* P < 0.001* IIA P = 0.821 P = 0.270 IIB P = 0.004* P = 0.003* IIIA P = 0.984 P = 0.993 IIIB P = 0.984 P = 0.149 Pathological T score T1a P = 0.928 P = 0.025* T1b P = 0.094 P = 0.009* T2a P = 0.023* P < 0.001* T2b P = 0.668 P = 0.923 T3 P = 0.273 P = 0.151 T4 P = 0.204 P = 0.783 Pathological N score N0 P < 0.001* P < 0.001* N1 P = 0.281 P = 0.023* N2+3 P = 0.472 P = 0.351 Pathological PL score PL0 P = 0.129 P = 0.013* PL1 P = 0.026* P < 0.001* PL2 P = 0.184 P = 0.079 PL3 P = 0.948
Expressed by P-values of the logrank test. PLC: pleural lavage cytology; PLC + : PLC-positive group; PLC − : PLC-negative group. *Statistical difference was confirmed with P < 0.05.
(uncorrected, PL2, PL3; 600.56, 609.28, 609.84). Conversion of the PLC + findings to PL3 (=T3) was, therefore, considered to be most appropriate. DFS curves that were re-estimated using the corrected PL score are shown in Fig. 4 to demonstrate the efficacy of correction.
DISCUSSION
The previously reported incidence of PLC + findings ranges from 2.7 to 41.7% [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . However, restricting to the papers of large series, the incidence of PLC + findings was found to be within the range of 3-6%. PLC + findings were reasonably estimated to be 4.58% in our study. Although the survival differences between the PLC + and PLC − groups are obvious, these differences may not have been due only to the sequelae of PLC + findings, because many of the other patient characteristics were also significantly different. For this reason, a Cox analysis was performed. All of the six variables analysed were statistically significant and PLC + findings were confirmed as a significantly poor prognostic factor. As for the results of the Cox analysis, many investigators [2, 4, 7, 8, 10, 12, 14] have reported that PLC + findings are an independent prognostic factor in lung cancer. However, their analysed explanatory variables are inconsistent. Above all, pN, which is widely believed to be the most important prognostic factor, is not included in many studies [2, 4, 7, 8, 10] . In some study, it is converted to a much rougher score, such as 'N0 vs. N1-3' [12] . In our study, the explanatory variables were simplified into two categories, one concerning the life expectancy (age and gender) and the other concerning the tumour growth (tumour size, pN and PL score); p-Stage and pT were not included because these factors may depend on other factors. We used the raw values of pN and PL score. If either of these scores was excluded from the explanatory variables, PLC + findings acquire a much smaller P-value (P = 0.001/OS without pN, P < 0.001/OS without PL score, P < 0.001/ DFS without pN, P < 0.001/DFS without PL score) and will be regarded as a much more important prognostic factor. However, this is nothing more than a statistical artefact. The impact of PLC + findings should not be overstated. We were simply analysing a particular stage of cancer progression.
The extent of pleural invasion is expressed by a pleural invasion score ranging from PL0 to PL3 and is considered to be useful in predicting prognosis [1] . PL3 is classified as T3 in the TNM classification; recently, PL1 and PL2 were classified as T2a or T2b (depending on tumour size) in the 7th Edition TNM classification [16, 17] . Moreover, in the 7th Edition TNM classification system, the classification of a malignant pleural effusion ( pleuritis carcinomatosa) increased from T4 to M1a [16, 17] because of its vicious prognosis. Before the appearance of a pleural effusion, occult (microscopic) dissemination must occur. Although this stage is not currently evaluated, it is detectable by the cytological examination of the pleural cavity, such as via PLC. Theoretically, patients with PLC + findings must be given a score of PL2 or higher because the cancer cells were exfoliated from the lung surface. However, 60.1% of the cases had been diagnosed as either PL1 or PL0 in our study. There is a discrepancy between the theory and clinical data. To evaluate the reliability of the staging, subset analysis was performed. In Stages IA and IB, the survival curves of the PLC + group were significantly worse than those of the PLC − group. As for the PL score, the survival curves of the PLC + group were also worse in the PL0 and PL1 groups. These findings suggested that the PLC + patients should not be included in these stages; instead, they should be classified in more advanced stages. As for the cause of discrepancy in the PL score, two possible explanations are conceivable: (i) cancer cells in the pleural cavity came from another origin, for example, exudation from the lymphatic channels or nodes; (ii) diagnosis of PL0 or PL1 was made using inappropriate section of histopathological specimen, for example, in the case with deep pleural indentation. The former is a most likely explanation, but it cannot be a single credible cause, because the ratio of N1-2 patients per PL0-1 patients in the PLC + group was only 31% in our data. We cannot get farther information because of the limitation of retrospective study. Although cancer cells in the pleural cavity do not always originate from the lung surface, microscopic dissemination should be recognized as a preliminary stage of the malignant pleural effusion. This is the reason why we proposed the re-staging by PLC + findings.
Although the PLC + findings were confirmed as a significantly poor prognostic factor in the Cox analysis, it would be more convenient if the PLC + findings were integrated with one of the existing TNM staging factors. Integration of PLC + findings into the PL score may positively contribute to the precise diagnosis of cancer advancement and, therefore, will be useful in evaluating its prognosis. Scoring PLC + findings as PL3 (=T3) should be a reasonable method to express the stage between PL2 (=T2a-b) and T4 (=M1a).
Standard operation for lung cancer should not be given up because of the positive findings of PLC. The DFS of the PLC + patients, whose stages were re-staged to be either IIB (T3N0) or IIIA (T3N1 and T3N2), were almost equal with that of the ordinary (PLC − group) Stage IIB or IIIA patients. Their survival is much better than that of the patients with malignant pleural effusion. Although we could not prove the efficacy of adjuvant therapy, due to the retrospective clinical data analysis, adjuvant chemotherapy will be indispensable. Intra-operative intra-pleural administration of hypotonic cysplatin [19] is a procedure of great interest. But farther investigations will be necessary to establish its efficacy.
CONCLUSION
Examining PLC in clinical practice is useful for detecting occult pleural dissemination before the appearance of a malignant pleural effusion. Evidence of PLC + findings should be treated as supplemental information to the precise diagnosis of PL score. Scoring PLC + findings as PL3 (=T3) was appropriate. However, standard operation should not be given up because of the positive PLC findings. The corrected survival curves of the PLC + group were almost equal with that of the ordinary stage IIB or IIIA patients.
